Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity

Human Gene Therapy

Volumn 28, Issue 5, 2017, Pages 437-448

  Li, Wenpeng ^a,b,c   Guo, Linjie ^a,b,c   Rathi, Purva ^d   Marinova, Ekaterina ^a,b,c   Gao, Xiuhua ^a,b,c   Wu, Meng Feng ^d   Liu, Hao ^d   Dotti, Gianpietro ^e   Gottschalk, Stephen ^a,b,c,f   Metelitsa, Leonid S ^a,b,c,f   Heczey, Andras ^a,b,c,d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c Department of Pediatrics ^*  (United States)

^d Dan L Duncan Cancer Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chimeric antigen receptor; glypican 3; hepatoblastoma; hepatocellular carcinoma; immunotherapy; rhabdoid tumor; T cell therapy

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GLYPICAN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; CD19 ANTIGEN; GLYPICAN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION ASSAY; CELL SURFACE; CELL SURVIVAL; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; STABLE EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; B CELL LYMPHOMA; CELL POLARITY; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

ANIMALS; ANTIGENS, CD19; CD28 ANTIGENS; CELL POLARITY; GLYPICANS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019235934     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.025     Document Type: Article

References (66)

1. Savoldo B, Dotti G. Chimeric antigen receptors (CARs) from bench-to-bedside. Immunol Lett 2013;155:40-42.
2. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med 2012;14:405-415.
3. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509- 1518.
4. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
6. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-1517.
7. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-549.
8. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra225.
9. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 doseescalation trial. Lancet 385:517-528.
10. Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 2015;107:djv048.
11. Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015;33:1688-1696.
12. Pule MA, Savoldo B, Myers GD, et al. Virusspecific T cells engineered to coexpress tumorspecific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-1270.
13. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050-6056.
14. Beatty GL, Haas AR, Maus MV, et al. Mesothelinspecific chimeric antigen receptor mRNAengineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2014;2: 112-120.
15. Abken H. Adoptive therapy with CAR redirected T cells: The challenges in targeting solid tumors. Immunotherapy 2015;7:535-544.
16. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends Mol Med 2012;18:377-384.
17. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 2006;24:e20-e22.
18. Lamers CHJ, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-912.
19. Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014;20: 6418-6428.
20. Wang XY, Degos Fo, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
21. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
22. Enan ET, El-Hawary AK, El-Tantawy DAE-A, Abu-Hashim MM, Helal NM. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions. Ann Diagn Pathol 2013;17:490-493.
23. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008;32:433-444.
24. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4, 387 tissue samples. Am J Clin Pathol 2008;129:899-906.
25. Chan ES, Pawel BR, Corao DA, et al. Immunohistochemical expression of glypican-3 in pediatric tumors: An analysis of 414 cases. Pediatr Dev Pathol 2013;16:272-277.
26. Levy M, Trivedi A, Zhang J, et al. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol 2012;43:695-701.
27. Tretiakova M, Zynger DL, Luan C, et al. Glypican 3 overexpression in primary and metastatic Wilms tumors. Virchows Arch 2015;466:67-76.
28. Zynger DL, Gupta A, Luan C, Chou PM, Yang GY, Yang XJ. Expression of glypican 3 in hepatoblastoma: An immunohistochemical study of 65 cases. Hum Pathol 2008;39:224-230.
29. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: A novel marker in testicular germ cell tumors. Am J Surg Pathol 2006;30:1570-1575.
30. Yorita K, Takahashi N, Takai H, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 2011;31:120-131.
31. Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009;100:1403-1407.
32. Ning S, Bin C, Na H, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012;39:351-357.
33. Yu MC, Lee YS, Lin SE, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 2012;19:S455-463.
34. Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol 2012; 18:2408-2414.
35. Fu SJ, Qi CY, Xiao WK, Li SQ, Peng BG, Liang LJ. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 2013;154:536-544.
36. Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci 2014;127:1565-1575.
37. Filmus J, Capurro M. Glypican-3: A marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013;280:2471-2476.
38. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-inman phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013;19:920-928.
39. Ikeda M, Ohkawa S, Okusaka T, et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci 2014;105:455-462.
40. Li K, Pan X, Bi Y, et al. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget 2015.
41. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumor-specific T-cell activation: A matter of costimulation?. Trends Immunol 23:240-245.
42. Kunkele A, Johnson AJ, Rolczynski LS, et al. Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD. Cancer Immunol Res 2015;3:368-379.
43. Krenciute G, Krebs S, Torres D, et al. Characterization and functional analysis of scFv-based cars to redirect T cells to IL13Ra2-positive glioma. Mol Ther 2015;24:354-363.
44. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106:3360-3365.
45. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cellmediated tumor eradication. Mol Ther 2010;18: 413-420.
46. Rabinovich BA, Ye Y, Etto T, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 2008;105: 14342-14346.
47. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Antiglypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008;68:9832- 9838.
48. Heczey A, Liu D, Tian G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014;124:2824-2833.
49. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453-1464.
50. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-941.
51. Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014;123:3750-3759.
52. Phung Y, Gao W, Man YG, Nagata S, Ho M. Highaffinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs 2012;4:592-599.
53. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: Comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. International journal of cancer. Int J Cancer 1984;34:339-348.
54. Hawkins ED, Hommel M, Turner ML, Battye FL, Markham JF, Hodgkin PD. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat Protoc 2007;2:2057-2067.
55. Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013; 21:1611-1620.
56. Filmus J, Selleck SB. Glypicans: Proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
57. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108:3890-3897.
58. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-5435.
59. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo M, Selvan S. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol Res 2011;51:170-182.
60. Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 2015;367:103-107.
61. Wu AA, Drake V, Huang H-S, Chiu S, Zheng L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology 2015;4:e1016700.
62. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of IL-10 and regulatory T-cells in cancer. Curr Opin Oncol 2013;25:637-645.
63. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014;257:107-126.
64. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther 2009;20:1229-1239.
65. Ali N, Flutter B, Sanchez Rodriguez R, et al. Xenogeneic graft-versus-host-disease in NOD-IL-2Rcnull mice display a T-effector memory phenotype. PLoS One 2012;7:e44219.
66. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822-1826.